Vivos Therapeutics, Inc. 2025 Annual Report: Key Investor Insights and Risks

Overview

Vivos Therapeutics, Inc. (“Vivos”, Nasdaq: VVOS) has released its Annual Report on Form 10-K for the fiscal year ending December 31, 2025. This comprehensive filing outlines significant strategic changes, financial risks, and operational developments that investors and shareholders should carefully consider. The company’s focus on integrating the Sleep Center of Nevada (SCN) business, its evolving business model, ongoing financial challenges, and regulatory environment are highlighted throughout the report.

Key Points for Investors

• Major Strategic Shift and Acquisition: Vivos undertook a significant pivot in its business model during 2024 and 2025, notably acquiring the Sleep Center of Nevada (SCN). The integration of SCN is central to Vivos’s future plans but presents integration and execution risks. The company openly acknowledges limited experience with this new model, which may yield unpredictable outcomes.
• Substantial Indebtedness: The SCN acquisition was financed through considerable debt. The company’s ability to service this debt is critical to its financial health. Any failure to meet debt obligations could have adverse effects on business operations, financial condition, and shareholder value.
• Ongoing Operating Losses and Liquidity Concerns: Vivos continues to report a history of operating losses and warns that it may never achieve positive cash flows or profitability. The company discloses that it will need to raise additional capital to fund and grow its business, which may lead to significant dilution for existing shareholders or increased debt service obligations. There is no guarantee that additional capital will be available on reasonable terms or in a timely manner.
• Material Weaknesses in Internal Controls: The company previously identified material weaknesses in its internal controls over financial reporting and cautions that future weaknesses may occur. This could result in material misstatements or failure to meet periodic reporting obligations, potentially impacting investor confidence and share price.
• Regulatory and Reimbursement Risks: Vivos’s business is subject to complex and evolving federal and state regulations, particularly relating to the practice of medicine, FDA compliance, and insurance reimbursement (including Medicare and Medicaid). Changes in payment rates or regulatory requirements could have a material adverse effect on operations and cash flows.
• Market and Product Uncertainties: The company faces risks from emerging competing technologies, changes in consumer preferences, and general market conditions for medical devices. The future revenue stream is anticipated to rely heavily on sales of its appliances and treatments, which are subject to market acceptance and regulatory approval.
• Nasdaq Listing Risks: Vivos’s common stock trades on the Nasdaq Capital Market under the symbol VVOS. The company warns that failure to meet Nasdaq’s minimum stockholders’ equity and bid price requirements could result in delisting, further impacting liquidity and share price.
• Volatility and Dilution: The company has issued a substantial number of shares and warrants in connection with financing activities. Large future sales of these shares could pressure the market price. Moreover, the stock has historically been highly volatile, and further volatility is expected.
• No Dividend Policy: Vivos does not anticipate paying cash dividends in the foreseeable future. Capital appreciation, if any, would be the sole source of gain for shareholders.
• Risks to Going Concern and Future Projections: The company states there are risks regarding its ability to continue as a going concern, generate positive cash flow, and achieve its operational or financial projections.
• Other Notable Risks: The report highlights risks related to product liability, activist shareholders, labor costs and shortages, protection of intellectual property, and the possibility that activist shareholders might disrupt strategic direction.

Summary Table of Material Risks and Potential Price-Sensitive Items

What Shareholders Should Watch

• Execution of SCN Integration: Shareholders should monitor updates related to the integration of the Sleep Center of Nevada and any statements regarding progress or setbacks.
• Debt Servicing and Liquidity: The ability of Vivos to service its substantial debt and secure future capital is critical to its viability and could significantly affect share value.
• Regulatory Developments: Changes in Medicare, Medicaid, or private insurance reimbursement policies, as well as any FDA compliance or enforcement actions, could move the share price.
• Nasdaq Compliance: Investors should watch for any communications from the company regarding its compliance with Nasdaq’s continued listing requirements, as a delisting could materially impact liquidity and value.
• Capital Raises and Dilution: Any announced capital raise, especially at a discount or with warrant coverage, could have an immediate impact on share price.
• Restatements or Control Issues: Any future material weaknesses in financial controls or financial restatements could erode investor confidence and cause price volatility.

Conclusion

The 2025 Annual Report for Vivos Therapeutics, Inc. presents a company at a crossroads, with substantial operational and financial risks alongside major strategic changes. While the integration of the SCN business and the pivot in the business model could create value, there are significant uncertainties and execution risks. The company’s ongoing liquidity and profitability challenges, exposure to regulatory and reimbursement changes, potential for further dilution, and risk of Nasdaq delisting are all highly material and should be considered by investors. These factors are likely to create ongoing volatility in the VVOS share price and may be price-sensitive in the short and medium term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. The summary is based on the company’s 2025 Annual Report and is not exhaustive. Investors should review the full filing and consult with financial advisors before making investment decisions.

View Vivos Therapeutics, Inc. Historical chart here